Hyderabad, October 15, 2016: (UNI) Hyderabad-headquartered Dr Reddy’s Laboratories Ltd (RDY) announced today that it has launched Aripiprazole tablets, USP, a therapeutic equivalent generic version of Abilify (aripiprazole) tablets in the United States market approved by the US Food & Drug Administration (USFDA).
The Abilify brand and generic tablets had US sales of approximately 3.1 billion dollars MAT for the most recent twelve months ending in August 2016 according to IMS Health, the Pharmaceutical said in a statement here.
Dr Reddy’s Aripiprazole tablets 2 mg, 5 mg, 10 mg, 15 mg, 20 mg, and 30 mg are available in bottle count sizes of 30. –United News of India
